An interventional study of Bevacizumab in Proliferative Diabetic Retinopathy - High Risk, sponsored by Christian Ophthalmic Surgery Expedition Network. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by Christian Ophthalmic Surgery Expedition Network · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Patients undergoing surgery for complications related to diabetes will be recruited.
Proliferative Diabetic Retinopathy patients undergoing pars plana vitrectomy will be randomized whether or not to receive intravitreal bevacizumab at the conclusion of the operation.
44 studies on the registry are indexed under Vitreous Hemorrhage; 4 are open to participants now.
This study's planned enrollment of 150 is above the median of 56 across 34 interventional studies indexed under Vitreous Hemorrhage.
Browse Vitreous Hemorrhage studies →This is the only study on the registry with Christian Ophthalmic Surgery Expedition Network as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject has uncontrolled hypertension (systolic > 200 mmHg or diastolic > 120 mmHg) despite adherence to a multiple anti-hypertensive medication regimen.
-
Receives postoperative bevacizumab
Procedure: Bevacizumab
Does NOT receive postoperative bevacizumab
Bevacizumab will be given immediately after surgery in the Treatment Group
Primary Outcome
Postoperative vitreous hemorrhage rate
Time frame: 6 months
Plan to share: Undecided — Not sure at this point.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.